Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 28, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 719,000 Ordinary Shares of 25 pence each.
- Purchase Date: August 28, 2013.
- Price Range: Highest price paid was 1,677.50 pence per share; lowest price paid was 1,662.50 pence per share.
- Treasury Holdings (Settled): 513,402,412 shares (9.48% of total issued share capital).
- Treasury Holdings (Including Unsettled): 515,554,412 shares (10.52% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,900,090,683 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 719,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.52% when including unsettled purchases. The filing does not provide comparative data for prior periods regarding these specific metrics.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback and the resulting capital structure.
Investor Verification Checklist
- Verify the total number of shares held in treasury (513,402,412 settled) against the latest quarterly or annual report.
- Confirm the total issued share capital to validate the 9.48% treasury ownership calculation.
- Check the status of the 2,152,000 shares purchased but not yet settled to confirm final treasury totals.
- Review the Annual General Meeting minutes from May 1, 2013, to confirm the scope of the share repurchase authority.